“…In rheumatoid arthritis, therapy with diverse therapeutic forms of TNF-a antagonists in all therapeutic forms is associated with relatively common and detectable autoimmune adverse events, including demyelinating disease, confirmed forms of MS, autoimmune hemolytic anemia, type 1 diabetes, a lupus-like syndrome, and cutaneous lupus rashes. Further, 11-57% of patients develop new or elevated antinuclear antibodies, usually shortly after therapy initiation or within 1 year [1,2,[11][12][13][14][15]. Approximately 7-15% of patients develop new antibodies against double-stranded DNA [13,15].…”